31 results match your criteria: "Veterans Affairs and Georgetown University[Affiliation]"

Background: Novel creatinine-based equations have recently been proposed but their predictive performance for cardiovascular outcomes in participants at high cardiovascular risk in comparison to the established CKD-EPI 2009 equation is unknown.

Method: In 9361 participants from the United States included in the randomized controlled SPRINT trial, we calculated baseline estimated glomerular filtration rate (eGFR) using the CKD-EPI 2009, CKD-EPI 2021, and EKFC equations and compared their predictive value of cardiovascular events. The statistical metric used is the net reclassification improvement (NRI) presented separately for those with and those without events.

View Article and Find Full Text PDF

The clinical implications of hypertension in addition to a high prevalence of both uncontrolled blood pressure and medication nonadherence promote interest in developing device-based approaches to hypertension treatment. The expansion of device-based therapies and ongoing clinical trials underscores the need for consistency in trial design, conduct, and definitions of clinical study elements to permit trial comparability and data poolability. Standardizing methods of blood pressure assessment, effectiveness measures beyond blood pressure alone, and safety outcomes are paramount.

View Article and Find Full Text PDF

Background Blood pressure ( BP ) varies over time within individual patients and across different BP measurement techniques. The effect of different BP targets on concordance between BP measurements is unknown. The goals of this analysis are to evaluate concordance between (1) clinic and ambulatory BP , (2) clinic visit-to-visit variability and ambulatory BP variability, and (3) first and second ambulatory BP and to evaluate whether different clinic targets affect these relationships.

View Article and Find Full Text PDF

Introduction: Automated office blood pressure (AOBP) has been proposed for blood pressure (BP) assessment in the office because it shows a strong association with the awake ambulatory BP. However, it remains unknown whether the presence or absence of an observer modulates AOBP readings.

Aim: To determine the difference between unattended and attended AOBP measurements through systematic review and meta-analysis.

View Article and Find Full Text PDF

Blood pressure (BP) is a physiological parameter with short- and long-term variability caused by complex interactions between intrinsic cardiovascular (CV) mechanisms and extrinsic environmental and behavioral factors. Available evidence suggests that not only mean BP values are important, but also BP variability (BPV) might contribute to CV events. Labile hypertension (HTN) is referred to sudden rises in BP and it seems to be linked with unfavorable outcomes.

View Article and Find Full Text PDF

Arterial hypertension (HT) is one of the most frequently recorded comorbidities among patients under antiangiogenic therapy. Inhibitors of vascular endothelial growth factor and vascular endothelial growth factor receptors are most commonly involved in new onset or exacerbation of pre-existing controlled HT. From the pathophysiology point of view, data support that reduced nitric oxide release and sodium and fluid retention, microvascular rarefaction, elevated vasoconstrictor levels, and globular injury might contribute to HT.

View Article and Find Full Text PDF

Background: Automated office blood pressure (AOBP) measurement is superior to conventional office blood pressure (OBP) because it eliminates the "white coat effect" and shows a strong association with ambulatory blood pressure.

Methods And Results: We conducted a cross-sectional study in 146 participants with office hypertension, and we compared AOBP readings, taken with or without the presence of study personnel, before and after the conventional office readings to determine whether their variation in blood pressure showed a difference in blood pressure values. We also compared AOBP measurements with daytime ambulatory blood pressure monitoring and conventional office readings.

View Article and Find Full Text PDF
Article Synopsis
  • Hypertension (HTN) is common in patients with HIV, raising their risk for cardiovascular disease.
  • Factors such as weakened immune function, long-term antiretroviral therapy, and demographic elements like age and gender contribute to higher HTN rates among these patients.
  • The review aims to summarize current findings on the connection between HIV infection and increased cardiovascular risk related to hypertension.
View Article and Find Full Text PDF

Air pollution is one of the greatest environmental threats and has been implicated for several adverse cardiovascular effects including arterial hypertension (HTN). However, the exact relationship between air pollution exposure and HTN is still unclear. Air contamination provokes oxidative stress, systemic inflammation, and autonomic nervous system imbalance that subsequently induce endothelial dysfunction and vasoconstriction leading to increased blood pressure.

View Article and Find Full Text PDF

Reply.

J Hypertens

November 2017

aDepartment of Cardiology and Clinical Research, Inselspital Bern, University of Bern, Bern, Switzerland bMount Sinai Icahn School of Medicine, New York, New York, USA cJagiellonian University Krakow, Kraków, Poland dDepartment of Clinical and Experimental Sciences, Clinica Medica, University of Brescia, Brescia, Italy eService de Néphrologie et Hypertension, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland fDepartment of Biomedical Sciences, Pacific Northwest University of Health Sciences, Yakima, Washington gHeart Disease Prevention Program, Division of Cardiology, Department of Medicine, C240 Medical Sciences, University of California, Irvine, California, USA hDepartment of Internal Medicine and Gerontology, Jagiellonian University Medical College, Krakow, Poland iDivision of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine,Tochigi, Japan jDepartment of Cardiology, University of Oslo, Ullevaal Hospital, Oslo, Norway kCardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA lDepartment of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, Paris, France mHypertension Unit, University of Ottawa Heart Institute, Ottawa, Ontario, Canada nDepartment of Medicine, Maastricht University Medical Center, Maastricht University, Maastricht, the Netherlands oDepartment of Heart Diseases, University of Bergen, Haukeland Hospital, Bergen, Norway pUniversity of Milano-Bicocca qIRCCS Istituto Auxologico Italiano, Milan, Italy rDepartment of Hypertension and Diabetology, Medical University of Gdańsk, Gdańsk, Poland sHypertension and Cardiovascular Research Clinic, Veterans Affairs and Georgetown University Medical Centers, Washington, District of Columbia, USA tDepartment of Cardiovascular, Neural and Metabolic Sciences, Ospedale S. Luca IRCCS Istituto Auxologico Italiano uDepartment of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy vImperial Clinical Trials Unit, Imperial College London, London, UK wHospital Clinico Unviersitario de Valencia, Valencia xDepartment of Nephrology, Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain yDepartment of Medicine, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Québec, Canada zDepartment of Nephrology and Hypertension, Friedrich-Alexander- University Erlangen-Nürnberg (FAU), Erlangen, Germany aaDivision of Nephrology and Hypertension, Department of Medicine bbAmerican Society of Hypertension, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA ccInternational Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London - Hammersmith Campus, London, UK ddDiabetes and Cardiovascular Center, University of Missouri School of Medicine eeDepartment Service, Harry S Truman Memorial Veterans Hospital ffDepartment of Medical Pharmacology and Physiology, University of Missouri School of Medicine, Columbia, Missouri, USA ggUniversity of Leuven, Leuven, Belgium hhDepartment of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China iiSUNY Downstate Medical Center, Brooklyn, New York, USA jjUniversity College London and NIHR University College London Hospitals Biomedical Research Centre, University College London, London, UK.

View Article and Find Full Text PDF

Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial).

Hypertension

October 2017

From the Division of Nephrology, Stanford University School of Medicine, CA (T.I.C., G.M.C.); Wake Forest School of Medicine, Winston-Salem, NC (D.M.R.); Division of Nephrology and Hypertension, University of Utah and Renal Section, Veterans Affairs Salt Lake City Health Care System (A.K.C.); Memphis Veterans Affairs Medical Center, TN (W.C.C.); Division of Cardiovascular Disease and Hypertension, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ (W.J.K.); Department of Medicine and Surgery, University of Milano-Bicocca, Italy (G.P.); St. Luke Hospital, Italian Auxology Institute, Milan, Italy (G.P.); Division of Renal Diseases and Hypertension, George Washington University, Washington, DC (D.R.); Intermountain Medical Center, Murray, UT (E.R.); Department of Cardiovascular Diseases, Mayo Clinic, Jacksonville, FL (B.S.); School of Medicine, National and Kapodistrian University of Athens, Greece (G.S.S., K.T.); Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.); Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA (P.K.W.); Primary Care Division, Clement J. Zablocki VA Medical Center, Milwaukee, WI (J.W.); Division of Nephrology and Hypertension, Case Western Reserve University, University Hospitals Cleveland Medical Center, OH (J.T.W.); and Department of Veterans Affairs and Georgetown University, Washington, DC (V.P.).

Unlabelled: Studies of visit-to-visit office blood pressure (BP) variability (OBPV) as a predictor of cardiovascular events and death in high-risk patients treated to lower BP targets are lacking. We conducted a post hoc analysis of SPRINT (Systolic Blood Pressure Intervention Trial), a well-characterized cohort of participants randomized to intensive (<120 mm Hg) or standard (<140 mm Hg) systolic BP targets. We defined OBPV as the coefficient of variation of the systolic BP using measurements taken during the 3-,6-, 9-, and 12-month study visits.

View Article and Find Full Text PDF

Expertise: no longer a sine qua non for guideline authors?

J Hypertens

August 2017

aDepartment of Cardiology and Clinical Research, Inselspital Bern, University of Bern, Bern, Switzerland bMount Sinai Icahn School of Medicine, New York, New York, USA cJagiellonian University Krakow, Kraków, Poland dDepartment of Clinical and Experimental Sciences, Clinica Medica, University of Brescia, Brescia, Italy eService de Néphrologie et Hypertension, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland fDepartment of Biomedical Sciences, Pacific Northwest University of Health Sciences, Yakima, Washington gHeart Disease Prevention Program, Division of Cardiology, Department of Medicine, C240 Medical Sciences, University of California, Irvine, California, USA hDepartment of Internal Medicine and Gerontology, Jagiellonian University Medical College, Krakow, Poland iDivision of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan jDepartment of Cardiology, University of Oslo, Ullevaal Hospital, Oslo, Norway kCardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA lDepartment of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, Paris, France mHypertension Unit, University of Ottawa Heart Institute, Ottawa, Ontario, Canada nDepartment of Heart Diseases, University of Bergen, Haukeland Hospital, Bergen, Norway oUniversity of Milano-Bicocca pIRCCS Istituto Auxologico Italiano, Milan, Italy qDepartment of Hypertension and Diabetology, Medical University of Gdansk, Gdańsk, Poland rHypertension and Cardiovascular Research Clinic, Veterans Affairs and Georgetown University Medical Centers, Washington, District of Columbia, USA sDepartment of Cardiovascular, Neural and Metabolic Sciences, Ospedale S. Luca IRCCS Istituto Auxologico Italiano tDepartment of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy uImperial Clinical Trials Unit, Imperial College London, London, UK vHospital Clinico Unviersitario de Valencia, Valencia wDepartment of Nephrology, Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain xDepartment of Medicine, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Québec, Canada yDepartment of Nephrology and Hypertension, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany zDivision of Nephrology and Hypertension, Department of Medicine aaAmerican Society of Hypertension, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA bbInternational Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London - Hammersmith Campus, London, UK ccDiabetes and Cardiovascular Center, University of Missouri School of Medicine ddDepartment Service, Harry S Truman Memorial Veterans Hospital eeDepartment of Medical Pharmacology and Physiology, University of Missouri School of Medicine, Columbia, Missouri, USA ffUniversity of Leuven, Leuven, Belgium ggDepartment of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China hhSUNY Downstate Medical Center, Brooklyn, New York, USA iiUniversity College London and NIHR University College London Hospitals Biomedical Research Centre, University College London, London, UK jjDepartment of Medicine, Masstricht University Medical Center, Maastricht University, Maastricht, the Netherlands.

: Several sets of guidelines have been published recently and more are in the works. The very recent American College of Physicians/American Academy of Family Practitioners guidelines were put together by a set of authors and consultants without any expertise in the topic under discussion, that is, hypertension. Although we are not maintaining that all guidelines should be written exclusively by experts, complete lack of expertise among guideline authors is not acceptable.

View Article and Find Full Text PDF

Expertise: No Longer a Sine Qua Non for Guideline Authors?

Hypertension

August 2017

From the Department of Cardiology and Clinical Research, Inselspital Bern, University of Bern, Switzerland (F.H.M., L.H., S.F.R.); Mount Sinai Icahn School of Medicine, New York, NY (F.H.M.); Jagiellonian University Krakow, Poland (F.H.M.); Department of Clinical and Experimental Sciences, Clinica Medica, University of Brescia, Italy (E.A.R.); Service de Néphrologie et Hypertension, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland (M.B.); Department of Biomedical Sciences, Pacific Northwest University of Health Sciences, Yakima, WA (W.J.E.); Heart Disease Prevention Program, Division of Cardiology, Department of Medicine, C240 Medical Sciences, University of California, Irvine (S.S.F.); Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Krakow, Poland (T.G.); Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan (K.K.); Department of Cardiology, University of Oslo, Ullevaal Hospital, Norway (S.E.K.); Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ (J.B.K.); Departments of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, France (S.L.); Hypertension Unit, University of Ottawa Heart Institute, ON, Canada (F.H.L.); Department of Heart Diseases, University of Bergen, Haukeland Hospital, Norway (P.L.-J.); University of Milano-Bicocca, IRCCS Istituto Auxologico Italiano, Italy (G.M.); Department of Hypertension and Diabetology, Medical University of Gdansk, Poland (K.N.); Hypertension and Cardiovascular Research Clinic, Veterans Affairs and Georgetown University Medical Centers, Washington DC (V.P.); Department of Cardiovascular, Neural and Metabolic Sciences, Ospedale S. Luca IRCCS Istituto Auxologico Italiano, Milan; Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy (G.P.); Imperial Clinical Trials Unit, Imperial College London, United Kingdom (N.P.); Hospital Clinico Unviersitario de Valencia, Spain (J.R.); Department of Nephrology, Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain (L.M.R.); Lady Davis Institute for Medical Research and Department of Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada (E.L.S.); Department of Nephrology and Hypertension, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Germany (R.E.S.); Division of Nephrology and Hypertension, Department of Medicine, and American Society of Hypertension, Drexel University College of Medicine, Philadelphia, PA (A.B.S.); International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London-Hammersmith Campus, United Kingdom (P.S.); Diabetes and Cardiovascular Center, University of Missouri School of Medicine, Columbia; Research Service, Harry S. Truman Memorial Veterans Hospital, Research Service, Columbia; Department of Medical Pharmacology and Physiology, University of Missouri School of Medicine, Columbia (J.R.S.); University of Leuven, Belgium (J.A.S.); Department of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China (J.W.); SUNY Downstate Medical Center, Brooklyn, NY (M.W.); and University College London and NIHR University College London Hospitals Biomedical Research Centre, University College London, UK (B.W.).

View Article and Find Full Text PDF

Hypertension is a global public health problem affecting one-fourth of the world's population. A subset of these patients with resistant hypertension presents a particular management problem and suffers a marked increase in cardiovascular risk. Treatment options have been limited, but the past decade has witnessed the emergence of catheter-based renal denervation to interrupt the sympathetic nervous system, long considered to play an important role in the development and maintenance of hypertension.

View Article and Find Full Text PDF

Automated office blood pressure (AOBP) has recently been shown to closely predict cardiovascular (CV) events in the elderly. Home blood pressure (HBP) has also been accepted as a valuable method in the prediction of CV disease. This study aimed to compare conventional office BP (OBP), HBP, and AOBP in order to evaluate their value in predicting CV events and deaths in hypertensives.

View Article and Find Full Text PDF
Article Synopsis
  • Fibromuscular dysplasia is a rare vascular disease mainly affecting young women, leading to nonatherosclerotic narrowing of renal arteries and resulting in secondary hypertension.
  • Noninvasive tests are often unreliable for detecting renal artery stenosis, with renal angiography being the most effective diagnostic tool.
  • The preferred treatment is percutaneous renal artery angioplasty, but delayed diagnosis may prevent blood pressure normalization, and ongoing monitoring is essential due to the possibility of stenosis recurrence.*
View Article and Find Full Text PDF

Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system.

Hypertension

September 2014

From the Veterans Affairs and Georgetown University Medical Centers, Washington, DC (V.P.); The First Cardiology Clinic, University of Athens, Ippokration Hospital, Athens, Greece (V.P., C.P.T.); Department of Cardiology, Flinders University, Bedford Park, Australia (A.S., D.P.C.); Monash Heart and Monash University, Melbourne, Australia (I.T.M., Y.M.); Royal Adelaide Hospital, Adelaide, Australia (M.I.W.); and University of Adelaide, Adelaide, Australia (S.G.W.).

Renal denervation has emerged as a novel approach for the treatment of patients with drug-resistant hypertension. To date, only limited data have been published using multielectrode radiofrequency ablation systems. In this article, we present the 12-month data of EnligHTN I, a first-in-human study using a multielectrode ablation catheter.

View Article and Find Full Text PDF

Transluminal renal sympathetic denervation (RDN) reduces blood pressure (BP) in patients with drug-resistant uncontrolled hypertension. We assessed the effect of RDN on heart rate, supraventricular and ventricular ectopic activity and indexes of heart rate variability in 14 patients with drug-resistant uncontrolled hypertension who were all responders to RDN (defined as a reduction in office systolic BP ⩾ 10 mm Hg) at baseline and at 1 and 6 months after the procedure using the multielectrode EnligHTN ablation catheter (St Jude Medical). Office and 24-h systolic and diastolic BP were significantly reduced both at 1 and 6 months after RDN and all patients were office BP responders.

View Article and Find Full Text PDF

Hypertension represents a major health problem with an appalling annual toll. Despite the plethora of antihypertensive drugs, hypertension remains resistant in a considerable number of patients, thus creating the need for alternative strategies, including interventional approaches. Recently, catheter-based renal sympathetic denervation has been shown to be fairly safe and effective in patients with resistant hypertension.

View Article and Find Full Text PDF

Blood pressure (BP) is a continuous risk factor for ischemic and atherosclerotic events such as stroke and ischemic heart disease, and controlling BP is a well-established component of any cardiovascular or cerebrovascular risk reduction regimen. In most patients, > or =2 medications with different mechanisms of action will be necessary to reach recommended BP goals. The neuroendocrine effects of the renin-angiotensin-aldosterone-system (RAAS) have proven to be excellent therapeutic targets for BP lowering.

View Article and Find Full Text PDF

Angiotensin-converting enzyme (ACE) inhibitors have been extensively used for the treatment of patients with cardiovascular disease, but several concerns have been raised about their efficacy in African American (AA) patients with heart failure, hypertension, and left ventricular hypertrophy. In this study the authors assessed the effect of ACE inhibitors on total and cardiovascular mortality in high-risk AA patients with angiographically proven coronary artery disease (CAD). This was a retrospective analysis of 810 AA men who underwent diagnostic coronary angiography between 1995 and 2003.

View Article and Find Full Text PDF